Zac Ezzone

2 months ago | bizjournals.com | Zac Ezzone

North Carolina is one of dozens of states suing the federal government over recent, abrupt cuts to bullions in public health funding. North Carolina has joined dozens of states suing the Trump administration over abrupt cuts to billions in public health funding. The lawsuit filed Tuesday against the U.S. Department of Health and Human Services is in response to the agency last week terminating more than $11 billion in grant funding, including about $230 million earmarked for North Carolina.

2 months ago | bizjournals.com | Zac Ezzone

The former public company has closed a funding round as it transitions from a startup to a commercial organization. A company in Research Triangle Park has closed a funding round as it transitions from a startup to a commercial organization. GreenLight Biosciences recently closed a Series C round, which included a $25 million investment from Just Climate, an investment business established by Generation Investment Management.

Mar 28, 2025 | bizjournals.com | Zac Ezzone

A Durham company is pushing back on media reports questioning the safety of its lead product as the firm begins its commercial launch. A Durham company is pushing back on a New York Times questioning the safety of its lead product as the firm begins its commercial launch.

Mar 28, 2025 | bizjournals.com | Zac Ezzone

A recent audit of N.C. Central's finances last year found more than $45 million in reporting errors. The North Carolina Officer of the State Auditor found recent financial reporting from N.C. Central University to be "grossly inaccurate," under previous leadership. A recent audit of the school's finances for the year that ended June 30, 2024, found more than $45 million in reporting errors.

Mar 28, 2025 | bizjournals.com | Zac Ezzone

One of the Triangle's major economic engines is at stake as the Trump administration seeks to slash research funding. Summer 2025 was supposed to mark a major inflection point for Andy Barrett’s Chapel Hill company. Barrett is the president of Cessation Therapeutics, a pharmaceutical startup developing a treatment for people struggling with fentanyl addiction. Early signs show its treatment could help patients – but changes in federal policy have thwarted, at least temporarily, Cessation's efforts.